Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 EUR | -.--% | -.--% | -88.89% |
04-12 | Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-06 | Oxurion Raises Additional Funds from Convertible Bonds Issue | MT |
Business Summary
Oxurion NV is aiming to build the leading global franchise in the treatment of Age-related macular degeneration (AMD), based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikr
ein inhibitor being developed as a potential new standard of care for AMD patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all AMD patients.
Number of employees: 20
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vials
58.6
%
| 0 | 74.3 % | 0 | 58.6 % | -65.16% |
Royalties
41.4
%
| 0 | 25.7 % | 0 | 41.4 % | -28.76% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Belgium
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -55.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ghoson Pascal
CEO | Chief Executive Officer | - | 12-27 |
Andy de Deene
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Anat Loewenstein
BRD | Director/Board Member | 64 | 01/05/23 |
James Hartmann
BRD | Director/Board Member | 58 | 12-27 |
Director/Board Member | - | 01/05/23 | |
Ghoson Pascal
CEO | Chief Executive Officer | - | 12-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,014,821,287 | 8,626,162,500 ( 95.69 %) | 0 | 95.69 % |
Company contact information
Sector
Sales per Business
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-88.89% | 617K | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- OXUR Stock
- Company Oxurion NV